Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Charles Simone, MD
Conference Coverage
Addition of Stereotactic Body Radiation Therapy to Systemic Therapy Improves Outcomes Among Patients With Oligometastatic, Oligoprogressive NSCLC
04/28/2024

Featuring Charles Simone, MD

Featuring Charles Simone, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that adding SBRT to systemic therapy is a strong and effective way to treat patients with oligometastatic or oligoprogressive non-small...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that adding SBRT to systemic therapy is a strong and effective way to treat patients with oligometastatic or oligoprogressive non-small...
At the Great Debates and Updates...
04/28/2024
Oncology
Jamie Chaft, MD, Memorial Sloan-Kettering Cancer Center
Conference Coverage
The Benefit of Perioperative Immunotherapy in Lung Cancer Treatment
04/28/2024

Featuring Jamie Chaft, MD

Featuring Jamie Chaft, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Jamie Chaft, MD, argued in favor of both pre- and post-operative immunotherapy in the treatment of lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Jamie Chaft, MD, argued in favor of both pre- and post-operative immunotherapy in the treatment of lung cancer.
At the Great Debates and Updates...
04/28/2024
Oncology
Charles Simone, MD
Conference Coverage
Non-Surgical Interventions for Patients With Stage 3 Non-Small Cell Lung Cancer
04/27/2024

Featuring Charles Simone, MD

Featuring Charles Simone, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.
At the Great Debates and Updates...
04/27/2024
Oncology
Charles Simone, MD
Conference Coverage
Non-Surgical Interventions for Patients With Stage 3 Non-Small Cell Lung Cancer
04/27/2024

Featuring Charles Simone, MD

Featuring Charles Simone, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.
At the Great Debates and Updates...
04/27/2024
Oncology
Christian Rolfo, MD, PhD
Videos
Using ctDNA to Monitor Patients With Lung Cancers
10/05/2023
At the Great Debates & Updates in Lung Cancer meeting, Chrisitian Rolfo, MD, PhD, discussed the use of ctDNA to monitor patients with lung cancers.
At the Great Debates & Updates in Lung Cancer meeting, Chrisitian Rolfo, MD, PhD, discussed the use of ctDNA to monitor patients with lung cancers.
At the Great Debates & Updates...
10/05/2023
Oncology
Karen Reckamp, MD
Videos
The Case for Chemotherapy Plus Immunotherapy for Patients With Low or Negative PD-L1
10/05/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Karen Reckamp, MD, debated in favor of using chemotherapy plus immunotherapy for patients with NSCLC and PD-L1 expressions of
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Karen Reckamp, MD, debated in favor of using chemotherapy plus immunotherapy for patients with NSCLC and PD-L1 expressions of
At the Great Debates & Updates...
10/05/2023
Oncology
Karen Reckamp, MD
Videos
Treatment Landscape for Patients With Metastatic NSCLC Without Actionable Mutations
10/05/2023
At the Great Debates & Updates in Lung Cancer Meeting in New York, Karen Reckamp, MD, gave an overview of the treatment landscape for patients with metastatic non-small cell lung cancers that do not have actionable mutations.
At the Great Debates & Updates in Lung Cancer Meeting in New York, Karen Reckamp, MD, gave an overview of the treatment landscape for patients with metastatic non-small cell lung cancers that do not have actionable mutations.
At the Great Debates & Updates...
10/05/2023
Oncology
Jamie Chaft, MD
Videos
The Case for Neoadjuvant Immunotherapy in Resectable NSCLC
10/05/2023
At the Great Debates & Updates meeting in New York, Jamie Chaft, MD, debated in favor of neoadjuvant immunotherapy in resectable non-small cell lung cancer.
At the Great Debates & Updates meeting in New York, Jamie Chaft, MD, debated in favor of neoadjuvant immunotherapy in resectable non-small cell lung cancer.
At the Great Debates & Updates...
10/05/2023
Oncology
Jamie Chaft, MD
Videos
The Case for Immunotherapy Alone for Patients With PD-L1-High NSCLC in the First-Line Setting
09/29/2023
At the Great Debates & Updates meeting in New York, Jamie Chaft, MD, debated in favor of using immunotherapy alone in the first-line setting for patients with high PD-L1 expression and non-small cell lung cancer.
At the Great Debates & Updates meeting in New York, Jamie Chaft, MD, debated in favor of using immunotherapy alone in the first-line setting for patients with high PD-L1 expression and non-small cell lung cancer.
At the Great Debates & Updates...
09/29/2023
Oncology
Misako Nagasaka, MD, PhD
Videos
The Case for Lorlatinib in ALK-Positive NSCLC
09/28/2023
At the Great Debates & Updates in Lung Cancer meeting, Misako Nagasaka, MD, PhD, debated in favor of lorlatinib over alectinib when considering treatment options for patients with ALK-positive non-small cell lung cancer (NSCLC).
At the Great Debates & Updates in Lung Cancer meeting, Misako Nagasaka, MD, PhD, debated in favor of lorlatinib over alectinib when considering treatment options for patients with ALK-positive non-small cell lung cancer (NSCLC).
At the Great Debates & Updates...
09/28/2023
Oncology

Advertisement

About

Formerly known as Perspectives in Thoracic Oncology, the lung cancer meeting you know and love is getting a makeover. With an updated name to reflect a more pronounced focus on targeted therapies, biomarker testing and precision medicine, year 25 of this educational gathering is getting practical. Personalized Therapies in Thoracic Oncology will go beyond chemotherapy and focus on the best way to treat your patients when traditional methods aren't cutting it. 

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use